A/Prof Gregorevic is Head of the Laboratory for Muscle Research and Therapeutics, and Deputy Director of the Centre for Muscle Research, in the Department of Physiology, within the School of Biomedical Sciences. His research employs gene delivery technologies and skeletal muscle as a model system to a) investigate mechanisms underlying the regulation of cell growth and adaptation in health and disease, and b) evaluate muscle-directed interventions for frailty associated with illness, injury, and ageing.
A/Prof Gregorevic is a Senior Research Fellow of the NHMRC and President of the Australasian Gene and Cell Therapy Society.A/Prof Gregorevic obtained his Ph.D. in Physiology from The University of Melbourne in 2001, for investigation of the processes of skeletal muscle repair and adaptation. From 2002 until 2008, he completed postdoctoral training at The University of Washington, during which time he helped to develop techniques enabling systemic delivery of genes to mammalian striated muscle in vivo, and adapted these methods to achieve the first "gene therapy" of a mouse model of a lethal muscular dystrophy. For his contributions to physiology as an early career researcher, he was awarded the 13th A.K. McIntyre Medal from the Australian Physiological Society. From 2008 until 2018, A/Prof Gregorevic was Head of the Laboratory for Muscle Research and Therapeutics, and Director of the Recombinant Viral Vector Facility at the Baker Heart and Diabetes Institute. In 2018, A/Prof Gregorevic was appointed to his current role at The University of Melbourne.Since 2008, A/Prof Gregorevic’s team has pioneered the use of recombinant viral vectors for investigating the mechanisms that regulate muscle attributes in vivo. Notable contributions include insight into processes driving follistatin-mediated muscle growth (2012), identification of the BMP axis as a positive regulator of muscle mass (2013), demonstration that Activins are negative regulators of muscle mass (2014), description of an essential role of the Hippo pathway in adult muscle (2015), use of integrated “omics” analyses to identify novel regulators of muscle growth (2016), proof-of-concept for a muscle-directed gene therapy as an intervention for cancer cachexia (2016), and evidence of synergistic roles of activins and myostatin as negative regulators of muscle mass (2017). His team has also helped develop customised recombinant viral vectors for numerous collaborative projects world-wide, contributing to important discoveries including functional recovery in a model of heart failure via a gene therapy targeting the PI3K-Akt pathway (2012), insight into mechanisms by which Actinins alter muscle phenotype (2013), a role for TWEAK-FN14 signalling in tumours as a driver of wasting in cancer cachexia (2015), identification of a metabolic mechanism in the developmental arrest of cardiomyocytes (2017), mechanisms of cross-talk from muscle to organs with exercise (2017), and insight into the mechanisms of action associated with a novel agent designed to treat Type 2 diabetes and muscle atrophy (2019).
Find out more about Paul Gregorevic's experience
Paul Gregorevic's highlights
FEATURED Journal article
Phosphorylation within the cysteine-rich region of dystrophin enhances its association with beta-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting
Read morePaul Gregorevic's selected work
Projects
Displaying the 10 most recent projects by Paul Gregorevic.
Project Types
10
Research Grant
Scholarly Works
Displaying the 115 most recent scholarly works by Paul Gregorevic.
Keyword Analysis
Credentials
Positions
Principal Research Fellow
Physiology
Education
Bachelor of Science
University of Melbourne
Doctor of Philosophy
University of Melbourne